宁波美诺华药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|--------------------------------------|-------------| | | | | | | √特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | | | | 融通基金管理有限公司 | | | 参与单位名称 | 上海景林资产管理有限公司 | | | | 太平洋寿险资管 | | | | 华泰证券（上海）资产管理有限公司 | | | | 华安基金管理有限公司 | | | | 海富通基金管理有限公司 | | | | 平安资产管理有限责任公司 | | | | 中信证券资产管理有限公司 | | | | 天风证券股份有限公司 | | | | 杭州优益增投资管理有限公司 | | | | 中银基金管理有限公司 | | | | 君和资本管理有限公司 | | | | 南方基金管理股份有限公司 | | | | 财通医药 | | ...

| 证券代码：603538 | 证券简称：美诺华 公告编号：2024-107 | | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | 宁波美诺华药业股份有限公司 4、申请事项：药品注册（境内生产） 5、注册分类：化学药品 3 类 6、受理号：CYHS2200731、CYHB2301708 7、药品批准文号：国药准字 H20249166 宁波美诺华药业股份有限公司（以下简称"公司"）全资子公司宁波美诺华 天康药业有限公司（以下简称"美诺华天康"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的氨溴特罗口服溶液《药品注册证书》，现 将相关情况公告如下： 一、药品相关信息 1、药品名称：氨溴特罗口服溶液 2、剂型：口服溶液剂 3、规格：100ml：盐酸氨溴索 150mg 与盐酸克伦特罗 100μg 关于全资子公司获得氨溴特罗口服溶液药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 8、药品批准文号有效期：至 2029 年 10 月 21 日 9、上市许可持有人：宁波 ...

| 证券代码：603538 | 证券简称：美诺华 公告编号：2024-108 | | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | 一、药品相关信息 （一）苯甲酸阿格列汀片（12.5mg） 宁波美诺华药业股份有限公司 1、药品名称：苯甲酸阿格列汀片 2、剂型：片剂 3、规格：12.5mg（按 C18H21N5O2计） 关于全资子公司获得苯甲酸阿格列汀片药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波美诺华药业股份有限公司（以下简称"公司"）全资子公司宁波美诺华 天康药业有限公司（以下简称"美诺华天康"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的苯甲酸阿格列汀片《药品注册证书》，现 将相关情况公告如下： 4、申请事项：药品注册（境内生产） 5、注册分类：化学药品 4 类 6、受理号：CYHS2302176 7、药品批准文号：国药准字 H20249177 8、药品批准文号有效期：至 2029 年 10 月 21 日 9、上市许可持有人：宁波美诺华天康 ...

宁波美诺华药业股份有限公司（以下简称"公司"）第五届监事会第七次会 议于 2024 年 10 月 29 日在公司会议室以现场结合通讯的方式召开。本次会议由 刘斯斌先生主持，会议应出席监事 3 名，实际出席监事 3 名。本次会议的召集和 召开符合《中华人民共和国公司法》等有关法律法规及《公司章程》《监事会议 事规则》的规定。 二、监事会会议审议情况 1、审议通过《2024 年第三季度报告》 具体内容详见公司于上海证券交易所网（www.sse.com.cn）等指定信息披露 媒体同日披露的《2024 年第三季度报告》。 监事会审核并发表如下意见：《2024 年第三季度报告》的编制和审核程序符 合法律、行政法规及监管机构的相关规定，报告客观、真实地反映了公司在报告 期的财务状况和经营成果，公司监事会及监事保证公司《2024 年第三季度报告》 所载资料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、 准确性和完整性承担法律责任。 | 证券代码：603538 | 证券简称：美诺华 | 公告编号：2024-106 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2024-105 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 特此公告。 二、董事会会议审议情况 1、审议通过《2024 年第三季度报告》 具体内容详见公司于上海证券交易所网（www.sse.com.cn）等指定信息披露 媒体同日披露的《2024 年第三季度报告》。 本议案已经公司董事会审计委员会全体成员审议通过，并同意将本议案提交 公司董事会审议。 表决结果：同意 5 票，反对 0 票，弃权 0 票。 第五届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 宁波美诺华药业股份有限公司（以下简称"公司"）第五届董事会第七次会 议于 2024 年 10 月 29 日在公司会议室以现场结合通讯的方式召开。本次会议由 姚成志先生主持，会议应出席董事 5 名，实际出席董事 5 名。公司监事、高级管 理人员列席了会议。本次会议的召集和召开符 ...

Revenue and Profit Performance - Revenue for the third quarter was RMB 341.2 million, a decrease of 1.46% year-over-year[2] - Net profit attributable to shareholders of the listed company for the third quarter was RMB 44.31 million, an increase of 87.08% year-over-year[2] - Revenue for the first three quarters of 2024 was RMB 949.08 million, an increase of 2.21% year-over-year[8] - Total operating income for the first three quarters of 2024 reached 949,078,888.15 RMB, a 2.2% increase compared to 928,533,649.58 RMB in the same period of 2023[16] - Net profit attributable to the parent company's shareholders in the first three quarters of 2024 was 63,250,382.67 RMB, up 16% from 54,538,412.55 RMB in the same period of 2023[18] - Basic earnings per share for the third quarter were RMB 0.20, an increase of 81.82% year-over-year[2] - Diluted earnings per share for the third quarter were RMB 0.19, an increase of 90.00% year-over-year[4] - Basic earnings per share for the first three quarters of 2024 was 0.29 RMB, up from 0.26 RMB in the same period of 2023[19] - Total comprehensive income for the first three quarters of 2024 was 67,882,973.44 RMB, a 13.7% increase from 59,718,451.47 RMB in the same period of 2023[19] Gross Profit and Operating Costs - Gross profit margin for the first three quarters was 31.88%, an increase of 2.37 percentage points compared to the first half of the year[8] - Operating costs for the first three quarters of 2024 were 895,078,452.62 RMB, a 2.5% increase from 873,176,116.06 RMB in the same period of 2023[16] - Sales expenses for the first three quarters of 2024 were 37,913,423.95 RMB, a 13.9% increase compared to 33,294,939.69 RMB in the same period of 2023[18] Cash Flow and Financial Activities - Operating cash flow for the first three quarters increased by RMB 188 million year-over-year, driven by revenue growth and improved accounts receivable management[9] - Operating cash flow increased to 71,996,591.12, compared to a negative cash flow of -115,740,458.85 in the previous period[20] - Net cash flow from investment activities was -84,071,680.68, an improvement from -136,442,440.85 in the prior period[20] - Net cash flow from financing activities was 34,162,461.02, down from 56,596,272.78 in the previous period[21] - Total cash and cash equivalents at the end of the period were 299,911,038.59, a decrease from 359,833,262.60 in the prior period[21] - Cash received from operating activities totaled 1,125,620,482.17, up from 938,348,870.53 in the previous period[20] - Cash paid for goods and services was 645,918,779.90, compared to 569,434,507.13 in the prior period[20] - Cash paid to employees and for employee benefits was 232,750,307.34, up from 221,918,527.36 in the previous period[20] - Cash received from investments was 498,559,927.67, down from 1,048,358,431.09 in the prior period[20] - Cash paid for investments was 582,631,608.35, a decrease from 1,184,800,871.94 in the previous period[20] - Cash received from financing activities was 760,134,748.59, up from 562,516,929.99 in the prior period[21] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 4.62 billion, an increase of 4.34% compared to the end of the previous year[4] - The company's total assets increased to 4,615,562,488.89 yuan as of September 30, 2024, compared to 4,423,515,920.66 yuan at the end of 2023[14] - The company's monetary funds increased to 565,449,907.87 yuan as of September 30, 2024, compared to 456,042,013.93 yuan at the end of 2023[13] - The company's inventory increased to 791,940,007.56 yuan as of September 30, 2024, compared to 612,599,551.54 yuan at the end of 2023[13] - The company's short-term borrowings increased to 624,025,409.03 yuan as of September 30, 2024, compared to 486,720,976.64 yuan at the end of 2023[14] - The company's long-term borrowings decreased to 187,500,000.00 yuan as of September 30, 2024, compared to 302,000,000.00 yuan at the end of 2023[14] - The company's total liabilities increased to 1,591,674,135.70 yuan as of September 30, 2024, compared to 1,378,266,648.67 yuan at the end of 2023[14] - The company's total non-current liabilities decreased to 678,404,760.23 yuan as of September 30, 2024, compared to 759,649,573.05 yuan at the end of 2023[14] - Total liabilities as of Q3 2024 stood at 2,350,700,783.63 RMB, an increase of 5% from 2,237,831,964.82 RMB in the same period of 2023[15] - Total equity attributable to the parent company's shareholders as of Q3 2024 was 2,171,096,611.69 RMB, a 3.6% increase from 2,096,251,882.49 RMB in the same period of 2023[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 29,752[10] - Ningbo Menovo Pharmaceutical Group Co., Ltd. holds 45,285,661 shares, accounting for 20.70% of the total shares[10] - Yao Chengzhi holds 12,070,253 shares, accounting for 5.52% of the total shares[10] Non-Recurring Gains and R&D Expenses - Non-recurring gains, primarily from government subsidies, contributed RMB 17.43 million in the third quarter[5] - R&D expenses for the first three quarters of 2024 amounted to 64,469,834.54 RMB, slightly higher than 64,348,322.51 RMB in the same period of 2023[18] Business Contributions - The company's CDMO and integrated formulation businesses, particularly the "Annual 3 Billion Tablets (Pellets) Export Solid Preparation Construction Project," significantly contributed to revenue growth[8]

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2024-104 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于"美诺转债"预计满足转股价格向下修正条件的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、可转换公司债券基本情况 （一）可转换公司债券发行上市概况 经中国证券监督管理委员会《关于核准宁波美诺华药业股份有限公司公开发 行可转换公司债券的批复》（证监许可[2020]2377 号）核准，2021 年 1 月 14 日， 宁波美诺华药业股份有限公司（以下简称"公司"）公开发行 52,000 万元可转换 公司债券，共发行 520 万张，每张面值 100 元，期限 6 年。2021 年 2 月 4 日起， 上述可转换公司债券在上海证券交易所挂牌交易，转债简称"美诺转债"，转债 代码"113618"。 "美诺转债"存续的起止日期为 2021 年 1 月 14 日至 2027 年 1 月 13 日，转 股期起止日 ...

Investment Rating - The report gives an "Accumulate" rating for the company, indicating a positive outlook for the stock over the next six months [5][68]. Core Insights - The company is expected to see revenue growth from 2024 to 2026, with projected revenues of 1.463 billion, 1.859 billion, and 2.263 billion yuan, representing year-on-year growth rates of 20.29%, 27.03%, and 21.77% respectively [5][68]. - The company has a strong focus on the integrated development of APIs, formulations, and CDMO services, which is expected to enhance its competitive position in the market [13][68]. - The demand for hypertension medications is anticipated to rise due to increasing prevalence, particularly for ARB and ACEI drugs, which will benefit the company's core API products [29][39]. - The company has established deep collaborations with major clients like KRKA and Merck, which are expected to provide stable long-term revenue streams [4][63]. Summary by Sections 1. Integrated Development Strategy - The company focuses on a three-pronged strategy involving CDMO, specialty APIs, and formulations, serving major global markets and covering various therapeutic areas [13][14]. - The company has optimized its production capacity and is positioned to benefit from the recovery of API prices [22][24]. 2. API Market Outlook - The company has a strong portfolio in hypertension medications, with expectations for price stabilization and profit release in key API products [2][29]. - The demand for ARB and ACEI drugs is projected to grow, driven by the increasing incidence of hypertension in China [29][39]. 3. Formulation Business Expansion - The company is actively expanding its formulation business, leveraging its API advantages to increase market share and brand influence [3][50]. - The number of formulation projects has significantly increased, with 19 products approved for market entry in 2023 [3][56]. 4. Client Collaborations - The company has deepened its partnerships with KRKA and Merck, enhancing its product lines and securing ongoing orders [4][63]. - The collaboration with KRKA has led to joint development projects and a stable supply chain, while the partnership with Merck is expected to yield new product launches [59][63]. 5. Financial Projections - The company forecasts significant revenue growth across its segments, with the API segment expected to generate revenues of 8.69 billion, 11.00 billion, and 13.13 billion yuan from 2024 to 2026 [68]. - The formulation segment is projected to grow rapidly, benefiting from the integration with the API business and increased self-research investments [66][68].

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2024-101 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：截至 2024 年 9 月 30 日，累计共有人民币 43,363,000 元"美诺转债"已转换为公司股票，转股数量为 1,169,471 股，占可转债开始转 股前公司已发行股份总额的 0.782%。 未转股可转债情况：截至 2024 年 9 月 30 日，尚未转股的可转债金额为 人民币 476,637,000 元，占可转债发行总量的 91.661%。 本季度转股情况：自 2024 年 7 月 1 日至 2024 年 9 月 30 日期间，转股的 金额为 36,000 元，因转股形成的股份数量为 1,392 股。 一、可转债发行上市概况 （一） 经中国证券监督管理委员会《关于核准宁波美诺华药业股份有限公 司公开 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2024-102 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于 2021 年股票期权与限制性股票激励计划 2024 年第三季度 自主行权结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次行权股票数量：2021 年股票期权与限制性股票激励计划首次授予股 票期权第二个行权期可行权数量为 2,061,231 股，截至 2024 年 9 月 30 日，累计 行权 0 股。预留授予股票期权第一个行权期可行权数量为 758,651 股，截至 2024 年 9 月 30 日，累计行权 0 股。 本季度行权股票数量：自 2024 年 7 月 1 日至 2024 年 9 月 30 日期间，首 次授予股票期权第二个行权期累计行权 0 股，占首次授予股票期权第二个行权期 可行权总量的 0%。预留授予股票期权第一个行权期累计行权 0 股，占预留授予 股票期权第 ...